Form 4: Personalis Inc. Executive Stephen Michael Moore Reports Stock Option Grant

Stephen Michael Moore, General Counsel of Personalis, Inc., reports the acquisition of stock options.

Summary

• On March 15, 2024, Stephen Michael Moore, General Counsel of Personalis, Inc., reported a transaction related to the company's stock.
• Moore acquired options to purchase 100,000 shares of Personalis common stock at an exercise price of $1.61 per share.
• The options vest in 36 equal monthly installments, beginning on April 15, 2024, and expire on March 15, 2034.
• Following the transaction, Moore directly owns derivative securities for 100,000 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a standard executive compensation practice. The grant itself is neither overwhelmingly positive nor negative.

Positives

• The grant of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• Companies like Illumina, Inc. and Exact Sciences Corp. also utilize stock options as part of their executive compensation plans.
• The size and vesting schedule of the grant are generally in line with industry practices for executives at similar levels.

Stakeholder Impact

• The stock option grant could incentivize the executive to improve company performance, potentially benefiting shareholders.
• The grant has a dilutive effect on existing shareholders, although the impact is likely to be small.

Key Dates